In the realm of biotechnology, forward-looking statements play a crucial role in shaping expectations and assumptions about a company’s future. Genflow Biosciences Plc, the only publicly listed longevity company in Europe, recently disclosed key preclinical activities in two of its lead programs. With the aim of securing European Clinical Trial Authorisation (CTA), Genflow is making significant strides in advancing its development activities. Collaborating with its CDMO partner, Exothera, the company is focused on ensuring that clinical supply production meets the highest standards of Good Manufacturing Practice (GMP).
Concurrently, pivotal efficacy studies are being conducted with Genflow’s independent CRO partners, Physiogenex and Accelera, to evaluate the effectiveness of GF-1002 in addressing both early and advanced stages of MASH. Additionally, Genflow has submitted a protocol amendment for its ongoing proof-of-concept clinical trial in aged dogs, refining the administration of its investigational product, GF-1004. By specifying the intravenous (IV) dose rate, the company aims to enhance delivery consistency and minimize the risk of adverse events, thereby prioritizing patient safety. Dr. Eric Leire, CEO of Genflow, emphasized the significance of these developments, highlighting the company’s commitment to advancing science-backed therapies for healthy aging. With a promising outlook characterized by non-dilutive funding, strategic partnerships, and favorable regulatory support, Genflow is poised to accelerate its innovative programs in the field of longevity.
Read more from finance.yahoo.com